echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > IBD: Endoscopic activity and baseline serum TNF-α levels in patients with Crohn's disease were associated with a clinical response to usanutsin.

    IBD: Endoscopic activity and baseline serum TNF-α levels in patients with Crohn's disease were associated with a clinical response to usanutsin.

    • Last Update: 2020-10-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract characterized by relapse and remission.
    its incidence and prevalence are increasing year by year, and its main therapeutic objectives are to achieve clinical and endoscopic remission and avoid complications such as fistula and stenosis.
    In the past few years, CD treatment options have expanded, and the emergence of conventional drugs such as corticosteroids, thiopental, and especially tumor necrotologist α (TNF-α) antagonists has significantly changed the treatment options for moderate to severe active CD.
    tumor necrosis factor α antagonists can induce and maintain clinical remission, but about half of patients lose their response to TNF-α antagonists after a period of treatment.
    ustekinumab is a monoclonal antibody against naloxyme 12 (IL-12) and white mesokine 23 (IL-23) p40 subi.
    currently approved as a treatment for moderate to severe active CD in the United States, Europe and other countries.
    study aims to study whether induced disease activity is associated with clinical response by analyzing serum C-reactive protein (CRP) levels and simple endoscopic scores for Crohn's disease (SES-CD).
    selected patients were moderate to severe active CD patients who planned to receive ustekinumab treatment.
    At weeks 0, 8, 24, and 48, the differences between responders and non-reactors were compared by assessing patient demographics, simple endoscopic score (SES-CD), ustekinumab and cytokine concentrations, and cell fractions.
    results showed that the clinical response and clinical remission rates of the 22 patients in the group were 59.1% and 31.8% in week 8, 68.2% and 45.5% in week 24, and 54.4% and 40.9% respectively in week 48.
    there was no significant difference in the demographics and disease characteristics of patients at baseline between responders and non-reactors.
    combination of low SES-CD and high serum TNF-α at baselines showed a good correlation with clinical response.
    the treatment, serum TNF-α concentration decreased.
    the baseline of the respondent, the proportion of CD4 plus TNF-α cells was significantly higher than that of the respondent.
    in respondents, the proportion of CD4 plus TNF-α cells decreased with treatment, but not in non-respondents.
    this study confirms that a combination of higher serum TNF-α concentrations at baseline and lower SES-CD can help clinicians choose the right treatment for moderate to severe CD patients.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.